News

DateTitle
May 23, 2023AgeX Therapeutics Announces Appeal of NYSE American Determination
May 12, 2023AgeX Therapeutics Reports First Quarter 2023 Financial Results
April 26, 2023AgeX Therapeutics Receives Stock Exchange Deficiency Letter
March 31, 2023AgeX Therapeutics Reports Fourth Quarter and Annual 2022 Financial Results
November 25, 2022AgeX Therapeutics Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
November 10, 2022AgeX Therapeutics Reports Third Quarter 2022 Financial Results
August 12, 2022AgeX Therapeutics Reports Second Quarter 2022 Financial Results
May 18, 2022Dr. Joanne Hackett Appointed Chairperson of AgeX Board of Directors
May 13, 2022AgeX Therapeutics Reports First Quarter 2022 Financial Results
March 29, 2022AgeX Therapeutics Reports Fourth Quarter and Annual 2021 Financial Results
December 14, 2021AgeX Therapeutics to Collaborate With University of California, Irvine, on Research Program for Exosome-Based Therapies for Certain Brain Disorders
November 30, 2021AgeX Therapeutics’ Licensee ImStem Biotechnology Announces First U.S. Multiple Sclerosis Patient Dosed with IMS001
November 23, 2021AgeX Therapeutics Receives Stock Exchange Deficiency Letter
November 12, 2021AgeX Therapeutics Reports Third Quarter 2021 Financial Results
August 13, 2021AgeX Therapeutics Reports Second Quarter 2021 Financial Results
July 23, 2021AgeX Therapeutics and LyGenesis Terminate Merger Negotiations
May 17, 2021AgeX Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
March 31, 2021AgeX Therapeutics Reports Fourth Quarter and Annual 2020 Financial Results and Provides Business Update
March 12, 2021AgeX Announces Preprint Article Relating to Regeneration, Aging, and Cancer
March 10, 2021AgeX Therapeutics to Collaborate with The Ohio State University to Generate Proof-of-Concept Animal Data for AgeX’s Brown Adipose Tissue (BAT) Cell Therapy Candidate for Diabetes and Obesity
March 02, 2021AgeX Therapeutics and LyGenesis to Negotiate Merger Agreement
December 22, 2020AgeX Therapeutics, Inc. Announces That Its Annual Meeting of Stockholders Will Be Conducted Online Only
November 16, 2020AgeX Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
November 16, 2020AgeX Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
October 28, 2020AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 to ImStem Biotechnology for Development of Cell Therapy Candidate IMS001 for COVID-19 and Acute Respiratory Distress Syndrome
September 09, 2020AgeX Therapeutics and Lineage Cell Therapeutics Announce Expansion of Agreement Related to ESI Clinical-grade Pluripotent Stem Cell Lines for Therapeutic Purposes
August 14, 2020AgeX Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
June 16, 2020AgeX Therapeutics and Pluristyx Announce Manufacturing, Marketing, and Distribution Agreement to Expand Access to Clinical-Grade Human Pluripotent Stem Cells for Therapeutic Applications
June 05, 2020AgeX Therapeutics Receives Stock Exchange Deficiency Letter
June 02, 2020AgeX Therapeutics and ImStem Biotechnology Sign Non-Binding Letter of Intent Regarding Investigational MSC Candidate IMS001 for COVID-19 and Other Causes of ARDS
May 29, 2020AgeX Therapeutics and Sernova to Collaborate to Engineer Universal Locally Immune Protected Cell Therapies for Type I Diabetes and Hemophilia A
May 21, 2020AgeX Therapeutics, Inc. Appoints Andrea Park as Chief Financial Officer
May 14, 2020AgeX Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
May 01, 2020AgeX Therapeutics Announces Reduction in Projected Cash Expenditures
March 30, 2020AgeX Therapeutics Reports Fourth Quarter and Annual 2019 Financial Results and Provides Business Update
March 20, 2020AgeX Therapeutics Licensee ImStem Biotechnology Announces FDA has Lifted the Hold and Cleared the Investigational New Drug Application for IMS001 for the Treatment of Multiple Sclerosis
February 28, 2020AgeX Therapeutics Researchers Publish Paper on the Age Reprogramming of Super-Centenarian Cells
February 03, 2020AgeX Therapeutics to Collaborate with University of California, Irvine on Neural Stem Cell Research Program for Huntington’s Disease and Other Neurological Disorders
January 29, 2020AgeX Therapeutics Enters Research Collaboration With Japanese Biopharma Company to Generate Hypoimmunogenic Cells
January 14, 2020AgeX Therapeutics to Participate at Four Conferences in January 2020
December 26, 2019AgeX Therapeutics Announces Drawdown of Second Tranche of Loan Facility from Juvenescence Ltd.
December 10, 2019AgeX Therapeutics and Lineage Cell Therapeutics Announce Issuance of U.S. Patent for Method of Generating Induced Pluripotent Stem Cells
December 09, 2019AgeX Therapeutics Issues Year-End Letter to Shareholders
November 14, 2019AgeX Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
November 08, 2019AgeX Therapeutics to Present at Investing in the Age of Longevity Conference
October 30, 2019AgeX Therapeutics and Juvenescence Publish Paper on Engineering Strategies for Universal Cells and Provide in Vivo Observation on Immunotolerance UniverCyteTM Technology Platform
October 11, 2019AgeX Therapeutics to Present at Metabesity 2019
September 09, 2019AgeX Therapeutics Presents at the Rodman & Renshaw Global Investment Conference
September 04, 2019AgeX Therapeutics Publishes Theoretical Basis of Human Cell Age-Reversal in the Journal Regenerative Medicine
August 14, 2019AgeX Therapeutics, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update
August 05, 2019Regenerative Medicine Leader Michael H. May Joins AgeX Board of Directors
July 09, 2019AgeX Therapeutics’ CEO Dr. Michael D. West to Present at Ending Age-Related Diseases: Investment Prospects & Advances in Research
May 15, 2019AgeX Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update
May 01, 2019AgeX Therapeutics to Participate at Biotech Investing in Longevity from Aikora Health and Foresight Institute
April 05, 2019AgeX Therapeutics to Present at Master Investor Show 2019
April 01, 2019AgeX Therapeutics Reports Fourth Quarter and Annual 2018 Financial Results and Provides Business Update
March 22, 2019AgeX Therapeutics Receives $4.5 Million From Exercise of Warrants
March 21, 2019AgeX Therapeutics to Present at Undoing Aging 2019, March 28-30 in Berlin, Germany
March 07, 2019LifeMap Sciences and iCarbonX Research Shenzhen Announce Strategic Collaboration
January 31, 2019AgeX Therapeutics to Present at Longevity Leaders Conference, February 4 in London
January 22, 2019AgeX Therapeutics’ CEO Dr. Michael D. West Presents at Precision Medicine World Conference 2019
January 10, 2019LifeMap Sciences, Tianjin Novogene and Shanghai Shanyi Announce Strategic Partnership to Offer Leading Clinical NGS Solution to the China Market
January 09, 2019AgeX Therapeutics Publishes Data in Peer-Reviewed Journal to Advance Potential Cell Therapy AgeX-BAT1 for Type II Diabetes and Obesity
January 02, 2019AgeX Therapeutics to Present at Biotech Showcase 2019
November 29, 2018AgeX Therapeutics, Inc. to Present Keynote Address at Advanced Stem Cell & Regenerative Medicine 2018 Conference
November 29, 2018AgeX Therapeutics, Inc. Shares Commence Trading on the NYSE American
September 17, 2018BioTime Updates Timeline For Distribution Of AgeX Shares To BioTime Shareholders – Regulatory Approvals In-Process; New Record Date To Be Set Shortly
September 04, 2018BioTime Closes $43.2 Million AgeX Share Sale Transaction With Juvenescence
August 16, 2018AgeX Therapeutics Acquires Technology To Regulate Immune Tolerance – Technology Supports Company’s Strategy For Off-The-Shelf (Allogeneic) Cell-Based Regenerative Medicine Products Through The Use Of The HLA-G Gene
August 02, 2018BioTime To Receive $21.6 Million In Cash And $21.6 Million In A Convertible/Redeemable Note For 14.4 Million Shares Of AgeX Therapeutics. Creates Alignment Between AgeX Therapeutics And Juvenescence Limited To Potentially Become Leader In The Field Of Aging
July 11, 2018AgeX Therapeutics CEO Dr. Michael D. West To Present At Ending Age-Related Diseases: Investment Prospects & Advances In Research, July 12 In New York City
July 10, 2018BioTime Announces July 31, 2018 Record Date For The Distribution Of AgeX Therapeutics Shares
June 11, 2018Agex Therapeutics Closes On $5 Million Strategic Investment From Juvenescence
June 05, 2018Agex Therapeutics Appoints John F. Mauldin To Board Of Directors
May 17, 2018Agex Therapeutics Ceo Dr. Michael D. West To Deliver Keynote Address At World Advanced Therapies & Regenerative Medicine Congress, May 18 In London
May 02, 2018Agex Announces Nih Grant Award
March 01, 2018Agex Therapeutics Ceo Dr. Michael D. West To Present At Three Conferences In March 2018
January 18, 2018Agex Ceo Michael D. West To Present In Plenary Session At The World Stem Cell Summit On “Stem Cell Innovations That Will Change The World”
January 06, 2018Agex Therapeutics To Present At Biotech Showcase Annual Conference
January 02, 2018AgeX Therapeutics Identifies Genes Implicated In Tissue Regeneration And Cancer
December 04, 2017AgeX Therapeutics Ceo Michael D. West To Participate In Roundtable Panel On The Path Forward For Stem Cell Therapy At Termis Americas’ Annual Conference On Tissue Engineering & Regenerative Medicine, December 6 In Charlotte, Nc
November 08, 2017AgeX Therapeutics Vp Of New Technology Discovery Aubrey De Grey To Serve On Aging & Longevity Panel At Ft Global Pharmaceutical And Biotechnology Conference, November 9-10 In London
October 26, 2017AgeX Therapeutics Ceo Michael D. West To Give Special Interview For The Economist’s Conference “The Business Of Longevity: Health Innovation For An Ageing World” October 27 In Hong Kong
September 21, 2017AgeX Therapeutics Ceo Michael D. West To Participate In Fireside Chat With J. Craig Venter At The Cell & Gene Therapy Ceo Forum
August 17, 2017AgeX Therapeutics Closes $10 Million Capital Raise
August 09, 2017AgeX Therapeutics Ceo Michael D. West, Ph.D. To Deliver Keynote Address On Biotechnology And Aging At Raad Festival
August 02, 2017AgeX Therapeutics Obtains $10 Million In Capital And Commences Operations

Sign Up for the Latest AgeX News

Please fill out the form below to stay up-to-date on the latest news, events and pipeline information from AgeX.